JoVE Journal
Cancer Research
Cancer Research
É necessário ter uma assinatura JoVE para assistir este Faça login ou comece sua avaliação gratuita.
Capítulos
Resumo
To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.